Imunon, Inc. (IMNN) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Mar 31, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Imunon, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Imunon, Inc.'s filing signal continuing negative.
earningsVibe SuperAnalyst™ Verdict: CONTINUING NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Continuing Negative
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Imunon, Inc. actually do?
Answer:
Imunon, Inc. is a clinical-stage biotechnology company focused on developing novel DNA-based treatments that harness the body's natural mechanisms. The company's lead program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, currently in Phase 3 trials. Imunon also has a DNA vaccine modality, PlaCCine, which has been explored for infectious diseases, including a COVID-19 booster vaccine candidate. The company's proprietary TheraPlas delivery technology is designed to protect and deliver DNA and mRNA therapeutics. Imunon operates with a focus on advancing its pipeline through clinical development, with no current product sales.
Question:
What are Imunon, Inc.'s revenue drivers?
Answer:
The company has not generated revenue from product sales and does not expect to in the near future. Its primary sources of cash have been proceeds from the issuance and sale of its common stock.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required